Melanoma News and Research

RSS

Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.

New study pinpoints key source of T cell "exhaustion"

Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies.

21 Mar 2023

Macrophages likely to be a potential target for ER+ breast cancer

Most immunotherapies that aim to increase T cell activity are ineffective in treating estrogen receptor-positive (ER+) breast cancer. A new study of invasive ER+ breast cancers led by researchers at the University of Pittsburgh School of Medicine implies that targeting a different type of immune cell called macrophages may be a more effective approach.

From University of Pittsburgh 20 Mar 2023

Immune landscape in invasive ER+ breast cancers reveals a macrophage-driven microenvironment

Most immunotherapies, which aim to boost T cell activity, work poorly in treating estrogen receptor-positive (ER+) breast cancer.

20 Mar 2023

New combination therapy regimen may reduce prostate cancer progression or death by 37%

TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.

20 Mar 2023

Neoadjuvant dual immunotherapy and chemotherapy improve outcomes in patients with resectable NSCLC

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).

20 Mar 2023

Highlighting a potential sex‐specific precision immunotherapy strategy

Immunotherapy is an effective form of treatment for various types of cancer. However, its effect on pancreatic cancer is restricted and varies between men and women. Karolinska Institutet scientists have observed a possible explanation for this gender difference.

17 Mar 2023

Deeper understanding of T-cell responses may lead to better, more personalized immunotherapies

For the first time, a research team has identified and analyzed the steps by which immune cells "see" and respond to cancer cells, providing insights into reasons some treatments may be effective for certain patients but not others.

9 Mar 2023

CD5-expressing dendritic cells help to prime T cell responses against cancer

Immunotherapy has transformed cancer care. In advanced melanoma, for example, the most fatal form of skin cancer, the five-year survival rate has risen from less than 10% to more than 50% since immunotherapy was introduced in 2011.

17 Feb 2023

Combination of two types of immune cells helps predict response to cancer immunotherapy

Thanks to a new prognostic method for detecting cancers including cancer of the large intestine, doctors could provide clearer disease prognoses and predict which patients will respond best to immunotherapy.

10 Feb 2023

Study sheds light on why lung tumors do not respond well to immunotherapy

Immunotherapy -; drug treatment that stimulates the immune system to attack tumors -; works well against some types of cancer, but it has shown mixed success against lung cancer.

6 Feb 2023

Scientists develop new design principles to improve cancer vaccines

A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology at Northwestern University.

1 Feb 2023

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023

Persistent tumor mutation load may help predict outcome of novel immunotherapies

Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.

27 Jan 2023

Improving cancer immunotherapies with bioengineered synthetic gene circuits

In two distinct studies, scientists show how synthetic biology can be used to address a challenging problem in cancer immunotherapy: the way immunotherapy-related approaches focused on the short-term killing of tumor cells could fail to eradicate tumors because tumor growth occurs on longer timescales.

19 Dec 2022

Different cancers carry distinctive genetic signatures

After analyzing data from a public repository, CD4-T, CD8-T cells, and Treg cells, a team of researchers led by bioinformatics Mabel Vidal from the University of Concepcion and working with researchers from MELISA Institute and other academic institutions discovered a distinctive genetic signature among subsets of infiltrating T cells of various types of cancer.

4 Nov 2022

Melanoma News and Research

New study pinpoints key source of T cell "exhaustion"

Macrophages likely to be a potential target for ER+ breast cancer

Immune landscape in invasive ER+ breast cancers reveals a macrophage-driven microenvironment

New combination therapy regimen may reduce prostate cancer progression or death by 37%

Neoadjuvant dual immunotherapy and chemotherapy improve outcomes in patients with resectable NSCLC

Highlighting a potential sex‐specific precision immunotherapy strategy

Deeper understanding of T-cell responses may lead to better, more personalized immunotherapies

CD5-expressing dendritic cells help to prime T cell responses against cancer

Combination of two types of immune cells helps predict response to cancer immunotherapy

Study sheds light on why lung tumors do not respond well to immunotherapy

Scientists develop new design principles to improve cancer vaccines

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Persistent tumor mutation load may help predict outcome of novel immunotherapies

Improving cancer immunotherapies with bioengineered synthetic gene circuits

Different cancers carry distinctive genetic signatures

New approach to clear early stage pre-cancerous tumor cells

New tool advances potential means to deliver gene therapy

Delicate strategy employed by pathogens to suppress pyroptosis

Antibiotics deplete intestinal flora and weaken the immune response

Researchers develop targeted immunotherapy to destroy tumor cells

Driving Support for Pharmaceutical Testing Through Continuous Innovation

From Memory to Metaplasticity: Unraveling the Brain's Secrets

Revolutionizing Mass Spectrometry: A Deep Dive into Plasmion’s SICRIT® Technology

Latest in Genomics